The firstgeneration EGFR-TKI represented by gefitinib and erlotinib, and the second generation EGFR-TKI represented by afatinib and dacomitinib have achieved desirable efficacy in the treatment of EGFR-mutant NSCLC patients [9]. Here, EGFR is linked to non-small cell lung carcinoma.